TABLE 2.
Front‐line MM prescribing trends by treatment regimen, 2011 to 2019.
| Front‐line MM prescriptions, n (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
2011 (n = 301) |
2012 (n = 464) |
2013 (n = 576) |
2014 (n = 641) |
2015 (n = 745) |
2016 (n = 907) |
2017 (n = 831) |
2018 (n = 917) |
2019 (n = 852) |
|
| Monotherapy | 40 (13) | 70 (15) | 59 (10) | 65 (10) | 51 (6.8) | 50 (5.5) | 30 (3.6) | 52 (5.7) | 29 (3.4) |
| Doublet | 144 (48) | 233 (50) | 232 (40) | 258 (40) | 300 (40) | 271 (30) | 234 (28) | 190 (21) | 160 (19) |
| Triplet | 108 (36) | 159 (34) | 270 (47) | 303 (47) | 376 (50) | 562 (62) | 543 (65) | 642 (70) | 617 (72) |
| Quadruplet | 8 (2.7) | 1 (0.2) | 15 (2.6) | 15 (2.3) | 17 (2.3) | 23 (2.5) | 22 (2.6) | 30 (3.3) | 43 (5.0) |
Abbreviations: MM, multiple myeloma.